17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/0s3w63gp9~d8s.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/0kllbnt_hzshd.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/053zyoym-_i67.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/0u2ayibg4ahb..js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/0i99rkyrer3ax.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_F1YwpydxFehTJxgSzTNBrUVRTQpv"],"IconMark"] 18:T510,

What does the future hold for sterile fill-finish CDMOs in a rapidly evolving market?

In this sponsored episode of The Top Line, Denis Johnson, CEO of Grand River Aseptic Manufacturing, discusses the capacity crunch facing U.S. sterile manufacturing and what it means for healthcare stakeholders. As acquisitions reduce available capacity, Annex 1 drives preference for isolator technology, and companies reshore production, competition for specialized sterile fill expertise is intensifying.

Johnson explains why segmentation and specialization are becoming critical differentiators in the CDMO space, particularly as biologics pipelines expand and product launches accelerate. He also shares how GRAM is investing in new facilities, high-volume syringe and cartridge capabilities, and workforce development to stay ahead of client demand while maintaining compliance and flexibility.

For B2B healthcare professionals, marketers and payers seeking clarity on supply chain resilience and manufacturing strategy, this episode delivers timely insight. Listen now to explore how leading CDMOs are preparing for the next wave of sterile manufacturing demand.

See omnystudio.com/listener for privacy information.

Inside the sterile fill capacity crunch (Sponsored)

The Top Line

Inside the sterile fill capacity crunch (Sponsored)